These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 12186976)

  • 1. Huntington's disease age-of-onset linked to polyglutamine aggregation nucleation.
    Chen S; Ferrone FA; Wetzel R
    Proc Natl Acad Sci U S A; 2002 Sep; 99(18):11884-9. PubMed ID: 12186976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polyglutamine aggregation behavior in vitro supports a recruitment mechanism of cytotoxicity.
    Chen S; Berthelier V; Yang W; Wetzel R
    J Mol Biol; 2001 Aug; 311(1):173-82. PubMed ID: 11469866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polyglutamine expansion mutation yields a pathological epitope linked to nucleation of protein aggregate: determinant of Huntington's disease onset.
    Sugaya K; Matsubara S; Kagamihara Y; Kawata A; Hayashi H
    PLoS One; 2007 Jul; 2(7):e635. PubMed ID: 17653262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative connection between polyglutamine aggregation kinetics and neurodegenerative process in patients with Huntington's disease.
    Sugaya K; Matsubara S
    Mol Neurodegener; 2012 May; 7():20. PubMed ID: 22583646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. polyglutamine aggregation nucleation: thermodynamics of a highly unfavorable protein folding reaction.
    Bhattacharyya AM; Thakur AK; Wetzel R
    Proc Natl Acad Sci U S A; 2005 Oct; 102(43):15400-5. PubMed ID: 16230628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biophysical underpinnings of the repeat length dependence of polyglutamine amyloid formation.
    Landrum E; Wetzel R
    J Biol Chem; 2014 Apr; 289(15):10254-10260. PubMed ID: 24596088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A linear lattice model for polyglutamine in CAG-expansion diseases.
    Bennett MJ; Huey-Tubman KE; Herr AB; West AP; Ross SA; Bjorkman PJ
    Proc Natl Acad Sci U S A; 2002 Sep; 99(18):11634-9. PubMed ID: 12193654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Examining polyglutamine peptide length: a connection between collapsed conformations and increased aggregation.
    Walters RH; Murphy RM
    J Mol Biol; 2009 Nov; 393(4):978-92. PubMed ID: 19699209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploding the Repeat Length Paradigm while Exploring Amyloid Toxicity in Huntington's Disease.
    Wetzel R
    Acc Chem Res; 2020 Oct; 53(10):2347-2357. PubMed ID: 32975927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Normal-repeat-length polyglutamine peptides accelerate aggregation nucleation and cytotoxicity of expanded polyglutamine proteins.
    Slepko N; Bhattacharyya AM; Jackson GR; Steffan JS; Marsh JL; Thompson LM; Wetzel R
    Proc Natl Acad Sci U S A; 2006 Sep; 103(39):14367-72. PubMed ID: 16980414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biodegradable delivery system containing a peptide inhibitor of polyglutamine aggregation: a step toward therapeutic development in Huntington's disease.
    Joshi AS; Thakur AK
    J Pept Sci; 2014 Aug; 20(8):630-9. PubMed ID: 24788406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutational analysis of the structural organization of polyglutamine aggregates.
    Thakur AK; Wetzel R
    Proc Natl Acad Sci U S A; 2002 Dec; 99(26):17014-9. PubMed ID: 12444250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interrupting sequence variants and age of onset in Huntington's disease: clinical implications and emerging therapies.
    Wright GEB; Black HF; Collins JA; Gall-Duncan T; Caron NS; Pearson CE; Hayden MR
    Lancet Neurol; 2020 Nov; 19(11):930-939. PubMed ID: 33098802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intra- and intermolecular beta-pleated sheet formation in glutamine-repeat inserted myoglobin as a model for polyglutamine diseases.
    Tanaka M; Morishima I; Akagi T; Hashikawa T; Nukina N
    J Biol Chem; 2001 Nov; 276(48):45470-5. PubMed ID: 11584007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical nucleus size for disease-related polyglutamine aggregation is repeat-length dependent.
    Kar K; Jayaraman M; Sahoo B; Kodali R; Wetzel R
    Nat Struct Mol Biol; 2011 Mar; 18(3):328-36. PubMed ID: 21317897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nucleation of protein aggregation kinetics as a basis for genotype-phenotype correlations in polyglutamine diseases.
    Sugaya K; Matsubara S
    Mol Neurodegener; 2009 Jul; 4():29. PubMed ID: 19602294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular dynamics simulations indicate a possible role of parallel beta-helices in seeded aggregation of poly-Gln.
    Stork M; Giese A; Kretzschmar HA; Tavan P
    Biophys J; 2005 Apr; 88(4):2442-51. PubMed ID: 15665127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling the polyglutamine aggregation pathway in Huntington's disease: from basic studies to clinical applications.
    Sugaya K
    Subcell Biochem; 2012; 65():353-88. PubMed ID: 23225011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amyloid-like features of polyglutamine aggregates and their assembly kinetics.
    Chen S; Berthelier V; Hamilton JB; O'Nuallain B; Wetzel R
    Biochemistry; 2002 Jun; 41(23):7391-9. PubMed ID: 12044172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aggregation landscapes of Huntingtin exon 1 protein fragments and the critical repeat length for the onset of Huntington's disease.
    Chen M; Wolynes PG
    Proc Natl Acad Sci U S A; 2017 Apr; 114(17):4406-4411. PubMed ID: 28400517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.